Evidence map›Paper›PMID 29298972›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2018

Human Papilloma Viruses and Their Genotype Distribution in Women with High Socioeconomic Status in Central Anatolia, Turkey: A Pilot Study.

Mert Ulaş Barut, Engin Yildirim, Mehmet Kahraman, Murat Bozkurt, Necat Imirzalioğlu, Ayhan Kubar, Eray Çalişkan, Sibel Sak, Tarık Aksu

Abstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. HPV genotype distribution among women with normal and abnormal cervical cytology in Turkey.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mert Ulaş BarutDepartment of Obstetrics and Gynecology, Harran University School of Medicine, Şanlıurfa, Turkey.
Engin YildirimDepartment of Obstetrics and Gynecology, Public Hospital, Malatya, Turkey.
Mehmet KahramanDepartment of Obstetrics and Gynecology, Public Hospital, Niğde, Turkey.
Murat BozkurtDepartment of Obstetrics and Gynecology, Sakarya University School of Medicine, Sakarya, Turkey.
Necat ImirzalioğluDepartment of Obstetrics and Gynecology, Health Research System In Vitro Fertilization (HRS IVF) Center, Ankara, Turkey.
Ayhan KubarDepartment of Obstetrics and Gynecology, Health Research System In Vitro Fertilization (HRS IVF) Center, Ankara, Turkey.
Eray ÇalişkanDepartment of Obstetrics and Gynecology, Bahcesehir University, Istanbul, Turkey.
Sibel SakDepartment of Obstetrics and Gynecology, Harran University School of Medicine, Şanlıurfa, Turkey.
Tarık AksuDepartment of Obstetrics and Gynecology, Health Research System In Vitro Fertilization (HRS IVF) Center, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND In the present study we retrospectively evaluated the results of outpatients who had an HPV analysis, and present objective evidence for the administration of preventive inoculation in our area. MATERIAL AND METHODS We retrospectively reviewed 532 outpatients who visited a single center between 2012 and 2016 and had an HPV infection analysis. The criteria for inclusion of patients with unhealthy cervix in the study were: erosion, chronic cervicitis, healed lacerations, hypertrophied cervix, and abnormal discharges from the cervix. RESULTS We found that 122 out of 532 patients were infected with HPV, and the rate of multiple infections was 59.0% (72/122). HR-HPV (group 1 carcinogens HPV-16 (18.9%, 23/122), HPV-18 (13.1%, 16/122), HPV- 31 (4.9%, 6/122), HPV-33 (3.3%, 4/122), HPV-35 (7.4.9%/122), HPV-39 (5.7%, 7/122), HPV-45 (5.7%, 7/122), HPV-51 (11.5%, 15/122); Group 3 LR-HPV; HPV-6 (31.1%, 38/122), HPV-11 (26.2%, 32/122), HPV-42 (9.0%, 11/122) and HPV-43 (4.9%, 6/122). In terms of linear-by-linear association test, no significant statistical difference was identified between years. The P value for HPV infection rate on year basis was P>0.05. CONCLUSIONS In this hospital-based retrospective analysis, HPV types were found to be similar to HPV types reported in developed countries. We firmly suggest that patients should be informed about the risk of HPV infection at early ages.

Indexed as

AdultCervix UteriFemaleGenotypeHumansMiddle AgedPapillomaviridaePapillomavirus InfectionsPilot ProjectsPrevalenceRetrospective StudiesSocial ClassTurkeyVaginal SmearsYoung Adult

Identifiers

PMID29298972
PMCPMC5764117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.